(Photo Courtesy: www.peoplecheck.de)
Sanofi and its animal health company Merial announced that the European Commission has approved NexGard Spectra (afoxolaner and milbemycin oxime), a soft, beef-flavored chew for dogs that provides a broad spectrum of internal and external parasite control in one monthly dose.
NexGard Spectra, a prescription-only product, has been approved in Europe for the treatment of flea and tick infestations, the prevention of heartworm disease and/or the treatment of intestinal worms (roundworms, hookworms and whipworm).
"The European approval comes less than a year after the highly successful launch of NexGard, the first monthly beef-flavored chew for the treatment of flea and tick infestations in dogs. NexGard Spectra offers the same tasty and easy to use product, but for both external and internal parasites in dogs. We are proud to bring yet another option to veterinarians in flea and tick and heartworm control. NexGard Spectra is another example of Merial's commitment to deliver innovative products that improve the health and wellbeing of animals," said Mr Carsten Hellmann, Merial CEO and Sanofi executive VP.
NexGard Spectra will be available in five different chew sizes for dogs of different weights and is a novel combination of two active ingredients.
Afoxolaner is a new generation ectoparasiticide, killing fleas and ticks on the skin of dogs before they lay eggs.
Milbemycin oxime acts as an endoparasiticide, killing parasites like heartworms, roundworms, hookworms, and whipworms that live inside the body of dogs. NexGard Spectra adds to the company's parasiticide portfolio for pets and offers a new option for veterinarians and pet owners.
NexGard Spectra will be offered in Europe through veterinary prescription only.
Studies showed that the highly palatable NexGard Spectra effectively treated flea and tick infestations in dogs for up to 30 days after treatment, while killing intestinal worms (roundworms, hookworms and whipworm) and preventing heartworm infection.